BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

73 related articles for article (PubMed ID: 36597128)

  • 1. Glofitamab, a Novel, Bivalent CD20-Targeting T-Cell-Engaging Bispecific Antibody, Induces Durable Complete Remissions in Relapsed or Refractory B-Cell Lymphoma: A Phase I Trial.
    Hutchings M; Morschhauser F; Iacoboni G; Carlo-Stella C; Offner FC; Sureda A; Salles G; Martínez-Lopez J; Crump M; Thomas DN; Morcos PN; Ferlini C; Bröske AE; Belousov A; Bacac M; Dimier N; Carlile DJ; Lundberg L; Perez-Callejo D; Umaña P; Moore T; Weisser M; Dickinson MJ
    J Clin Oncol; 2021 Jun; 39(18):1959-1970. PubMed ID: 33739857
    [TBL] [Abstract][Full Text] [Related]  

  • 2. T and NK cells of B cell NHL patients exert cytotoxicity against lymphoma cells following binding of bispecific tetravalent antibody CD19 × CD3 or CD19 × CD16.
    Pörtner LM; Schönberg K; Hejazi M; Brünnert D; Neumann F; Galonska L; Reusch U; Little M; Haas R; Uhrberg M
    Cancer Immunol Immunother; 2012 Oct; 61(10):1869-75. PubMed ID: 22976535
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mosunetuzumab Safety Profile in Patients With Relapsed/Refractory B-cell Non-Hodgkin Lymphoma: Clinical Management Experience From a Pivotal Phase I/II Trial.
    Matasar M; Bartlett NL; Shadman M; Budde LE; Flinn I; Gregory GP; Kim WS; Hess G; El-Sharkawi D; Diefenbach CS; Huang H; To I; Parreira J; Wu M; Kwan A; Assouline S
    Clin Lymphoma Myeloma Leuk; 2024 Apr; 24(4):240-253. PubMed ID: 38195322
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Molecular assessment of intratumoral immune cell subsets and potential mechanisms of resistance to odronextamab, a CD20×CD3 bispecific antibody, in patients with relapsed/refractory B-cell non-Hodgkin lymphoma.
    Brouwer-Visser J; Fiaschi N; Deering RP; Cygan KJ; Scott D; Jeong S; Boucher L; Gupta NT; Gupta S; Adler C; Topp MS; Bannerji R; Duell J; Advani RH; Flink DM; Chaudhry A; Thurston G; Ambati SR; Jankovic V
    J Immunother Cancer; 2024 Mar; 12(3):. PubMed ID: 38519055
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Pharmacological characteristics and clinical outcomes of Epcoritamab (recombinant) (Epkinly
    Takaura K; Ando H; Ganoza ER
    Nihon Yakurigaku Zasshi; 2024; 159(1):61-68. PubMed ID: 38171842
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Characterization of anti-CD79b/CD3 bispecific antibody, a potential therapy for B cell malignancies.
    Wang J; Li C; He K; Kuang Z; Lu J; Yao Y; He F; Li N; Li L; Fu F; Wu Z; Zhou S; Kang D; Qiu X; Wu M; Liu Y; Cao X; Xu M; Chen B; Wu W; Guo F
    Cancer Immunol Immunother; 2023 Feb; 72(2):493-507. PubMed ID: 35963895
    [TBL] [Abstract][Full Text] [Related]  

  • 7. First-in-human study of JNJ-67571244, a CD33 × CD3 bispecific antibody, in relapsed/refractory acute myeloid leukemia and myelodysplastic syndrome.
    Narayan R; Piérola AA; Donnellan WB; Yordi AM; Abdul-Hay M; Platzbecker U; Subklewe M; Kadia TM; Alonso-Domínguez JM; McCloskey J; Bradford K; Curtis M; Daskalakis N; Guttke C; Safer K; Hiebert B; Murphy J; Li X; Duchin K; Esteban D
    Clin Transl Sci; 2024 Mar; 17(3):e13742. PubMed ID: 38494922
    [TBL] [Abstract][Full Text] [Related]  

  • 8. CLN-978, a novel half-life extended CD19/CD3/HSA-specific T cell-engaging antibody construct with potent activity against B-cell malignancies with low CD19 expression.
    Meetze K; Mehta NK; Li B; Michaelson JS; Baeuerle PA
    J Immunother Cancer; 2023 Aug; 11(8):. PubMed ID: 37586770
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Safety and tolerability of AMG 330 in adults with relapsed/refractory AML: a phase 1a dose-escalation study.
    Ravandi F; Subklewe M; Walter RB; Vachhani P; Ossenkoppele G; Buecklein V; Döhner H; Jongen-Lavrencic M; Baldus CD; Fransecky L; Pardee TS; Kantarjian H; Yen PK; Mukundan L; Panwar B; Yago MR; Agarwal S; Khaldoyanidi SK; Stein A
    Leuk Lymphoma; 2024 May; ():1-11. PubMed ID: 38712673
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Flotetuzumab as a salvage immunotherapy in advanced CD123-positive hematological malignancies, a phase 1 pilot study.
    Aldoss I; Zhang J; Robbins M; Song J; Al Malki MM; Otoukesh S; Sandhu K; Agrawal V; Herrera AF; Popplewell LL; Ghoda L; Stein A; Marcucci G; Forman S; Pullarkat V
    Leuk Lymphoma; 2024 Apr; ():1-9. PubMed ID: 38629176
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Sinonasal Lymphoma Presenting as a Probable Sanctuary Site for Relapsed B Acute Lymphoblastic Leukaemia: A Case Report and Review of the Literature.
    Lim WY; Care R; Lau M; Chiruka S; Dawes PJ
    Case Rep Hematol; 2015; 2015():697957. PubMed ID: 26697242
    [TBL] [Abstract][Full Text] [Related]  

  • 12. T-Cell Engagers-The Structure and Functional Principle and Application in Hematological Malignancies.
    Cech P; Skórka K; Dziki L; Giannopoulos K
    Cancers (Basel); 2024 Apr; 16(8):. PubMed ID: 38672662
    [TBL] [Abstract][Full Text] [Related]  

  • 13. New immune cell engagers for cancer immunotherapy.
    Fenis A; Demaria O; Gauthier L; Vivier E; Narni-Mancinelli E
    Nat Rev Immunol; 2024 Jan; ():. PubMed ID: 38273127
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Bispecific Antibodies in Hematological Malignancies: A Scoping Review.
    Omer MH; Shafqat A; Ahmad O; Alkattan K; Yaqinuddin A; Damlaj M
    Cancers (Basel); 2023 Sep; 15(18):. PubMed ID: 37760519
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Bi- and trispecific immune cell engagers for immunotherapy of hematological malignancies.
    Tapia-Galisteo A; Álvarez-Vallina L; Sanz L
    J Hematol Oncol; 2023 Jul; 16(1):83. PubMed ID: 37501154
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Safety of AFM11 in the treatment of patients with B-cell malignancies: findings from two phase 1 studies.
    Topp M; Dlugosz-Danecka M; Skotnicki AB; Salogub G; Viardot A; Klein AK; Hess G; Michel CS; Grosicki S; Gural A; Schwarz SE; Pietzko K; Gärtner U; Strassz A; Alland L; Mayer J
    Trials; 2023 Jan; 24(1):4. PubMed ID: 36597128
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A tetravalent bispecific TandAb (CD19/CD3), AFM11, efficiently recruits T cells for the potent lysis of CD19(+) tumor cells.
    Reusch U; Duell J; Ellwanger K; Herbrecht C; Knackmuss SH; Fucek I; Eser M; McAleese F; Molkenthin V; Gall FL; Topp M; Little M; Zhukovsky EA
    MAbs; 2015; 7(3):584-604. PubMed ID: 25875246
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Bispecific T-Cell Engager (BiTE) Antibody Construct Blinatumomab for the Treatment of Patients With Relapsed/Refractory Non-Hodgkin Lymphoma: Final Results From a Phase I Study.
    Goebeler ME; Knop S; Viardot A; Kufer P; Topp MS; Einsele H; Noppeney R; Hess G; Kallert S; Mackensen A; Rupertus K; Kanz L; Libicher M; Nagorsen D; Zugmaier G; Klinger M; Wolf A; Dorsch B; Quednau BD; Schmidt M; Scheele J; Baeuerle PA; Leo E; Bargou RC
    J Clin Oncol; 2016 Apr; 34(10):1104-11. PubMed ID: 26884582
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Functionally Defective T Cells After Chemotherapy of B-Cell Malignancies Can Be Activated by the Tetravalent Bispecific CD19/CD3 Antibody AFM11.
    Duell J; Lukic DS; Karg M; Reusch U; Koch J; Zhukovsky EA; Rajkovic E; Treder M; Rasche L; Eisele F; Einsele H; Topp MS
    J Immunother; 2019 Jun; 42(5):180-188. PubMed ID: 31090657
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 4.